Clinical Trials Browser

Phase 2 × Brain Neoplasms × irinotecan sucrosofate × Clear all

NCT05255666 2023-07-11

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Phase 2 Withdrawn

Brain Neoplasms, Triple Negative Breast Neoplasms